Trials / Completed
CompletedNCT01224093
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
A Multicentre, Observational, Prospective Study to Assess the Safety Profile of Rituximab in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (B-CLL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 219 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will evaluate the safety of MabThera/Rituxan (rituximab) in combination with chemotherapy in patients with previously untreated or relapsed/refractory B cell-lineage chronic lymphocytic leukaemia. Data will be collected from each patient for 6-12 months, depending on the prescribed chemotherapy regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chemotherapy | as prescribed |
| DRUG | rituximab [MabThera/Rituxan] | as prescribed |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2010-10-19
- Last updated
- 2016-11-02
Locations
55 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01224093. Inclusion in this directory is not an endorsement.